Deloitte.



18th Annual Pharmaceutical and Medical Device Compliance Congress Chief Compliance Officer Round Table

November 6, 2017

Panel Introductions



Moderator: Paul Silver
Principal, Regulatory & Compliance
Life Sciences Leader, Deloitte & Touche LLP
Atlanta, Georgia



Jill Dailey, MBA, JD Vice President and Chief Compliance Officer Incyte Wilmington, DE



Margaret K. Feltz, MA, JD
Chief Ethics and Compliance Officer
Purdue Pharma LP
Stamford, CT



Sujata T. Dayal, JD Vice President, Health Care Compliance & Privacy, Pharmaceuticals Group Johnson & Johnson Titusville, NJ



Arjun Rajaratnam, JDChief Compliance Officer
Smith & Nephew
Raleigh, NC



Today's Topics



Risks in an Era of New Business Models



Globalization & Regulatory Trends



The Future of Ethics & Compliance

Market Dynamics

- Market Access and Reimbursement
- New Drugs and Devices Hitting the Market
- Mergers/Acquisitions/Joint Ventures
- Quickly-Changing Technology



Empowerment of Compliance



Holistic

Fully integrated compliance:

- Partnership across all business boundaries
- Compliance incentives complementing business incentives
- Culture measured and recognized as a compliance risk factor
- Compliance is at forefront of business decisions



Reactive

Defensive compliance

- Remediation focused
- Limited resource
- Prescriptive processes
- Inadequate ownership
- Minimal training



Passive

Superficial compliance:

- Enforcement culture
- Fragmented resources
- Misalignment of local and global objectives
- Compliance consulted at end of decision



Operational

Transactional compliance:

- Simplistic training
- Remediation distracts from proactive approach
- Providing adequate processes of compliance
- Ineffective compliance incentives

Strategic

Embedded compliance:

- Compliance technology enhances daily business activities
- Local affiliates input to global process design
- Advanced training programs
- Tone at middle relays consistent messaging

Lack of compliance focus


Emerging

Evolving

Mature

Audience Polling

"In relation to this chart, where do you feel your organization falls within the compliance maturity continuum?"



Empowerment of compliance

focus

Mark on Chart

Topic 1: Risks in an Era of New Business Models

With new business models, there is a need to "share" risk.

What are some recommendations for navigating the potential compliance risks when partnering with third parties to conduct business?

Audience Polling

"As companies look at new business models, how likely is your organization to pursue a collaboration in the next two years to commercialize a product (merger, acquisition, licensing, joint venture, etc.)?"

- A. Unlikely
- B. Already collaborating with other partners
- C. Very likely
- D. Both B & C



Topic 1: Risks in an Era of New Business Models

We are no longer simply selling products but "healthcare solutions."

The industry has moved from selling products to "healthcare solutions." How has this shift impacted your approach to risk management and compliance?

Topic 2: Globalization & Regulatory Trends

Managing risk across markets


What are the global risks in the industry?

How are risks managed in a global environment?

Audience Polling

"How integrated is your compliance program?"

- A. Compliance is centrally managed and fully standardized across the globe.
- B. Compliance is driven by local/regional compliance teams.
- C. Our compliance function is centralized but not yet standardized into other regions.



Topic 2: Globalization & Regulatory Trends

Regulations continue to evolve and become even more region-specific.

What types of challenges have you encountered when implementing a global compliance program?

The Future of Ethics & Compliance

Audience Polling

"Which business area below do you believe is the biggest compliance challenge your company will deal with over the next couple of years?" (choose one)



- Distribution channels
- Global markets
- New promotional activities (i.e., digital, co-marketing)
- Market access
- Integrating compliance requirements in business systems
- Other

Topic 3: The Future of Ethics & Compliance

Do you expect investments in compliance infrastructure to increase in the future or will compliance leaders be expected to do more with less?


In your opinion, what can enable greater efficiencies?

Topic 3: The Future of Ethics & Compliance

What changes do you foresee for those who pursue a career path in compliance?

What will advancement look like and what skills will be required to be successful in the future?

Deloitte.



Thank you!

Deloitte.

This presentation contains general information only and Deloitte is not, by means of this presentation, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This presentation is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor.

Deloitte shall not be responsible for any loss sustained by any person who relies on this presentation.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.